Octreotide Alternatives Compared
| Octreotide | Sandostatin | Sandostatin LAR Depot |
|
|---|
| Octreotide | Sandostatin (octreotide) | Sandostatin LAR Depot (octreotide) |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Prescribed for Carcinoid Tumor, Acromegaly, Vasoactive Intestinal Peptide Tumor. May also be prescribed off label for Diarrhea, Diabetes - Type 1, Dumping Syndrome, Gastrinoma, Glucagonoma... View more |
Prescription only
Prescribed for Carcinoid Tumor, Acromegaly, Vasoactive Intestinal Peptide Tumor. Sandostatin may also be used for purposes not listed in this medication guide. |
Prescription only
Prescribed for Carcinoid Tumor, Acromegaly, Vasoactive Intestinal Peptide Tumor. Sandostatin LAR Depot may also be used for purposes not listed in this medication guide. |
Related suggestions Carcinoid Tumor
Vasoactive Intestinal Peptide Tumor
Popular comparisons
|
|||||||||||||||||||||||
| More about Octreotide | More about Sandostatin (octreotide) | More about Sandostatin LAR Depot (octreotide) | ||||||||||||||||||||||||
| Generic Status | ||||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Octreotide has an average rating of 7.6 out of 10 from a total of 17 ratings on Drugs.com. 69% of reviewers reported a positive effect, while 8% reported a negative effect. |
Sandostatin has an average rating of 8.0 out of 10 from a total of 7 ratings on Drugs.com. 71% of reviewers reported a positive effect, while 0% reported a negative effect. |
Sandostatin LAR Depot has an average rating of 8.3 out of 10 from a total of 6 ratings on Drugs.com. 75% of reviewers reported a positive effect, while 0% reported a negative effect. |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Side Effects | ||||||||||||||||||||||||||
|
Commonly reported side effects include:
See also: octreotide side effects in more detail. |
Common side effects include:
See also: Sandostatin side effects in more detail. |
See also: Sandostatin LAR Depot side effects in more detail. |
||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all octreotide prices |
View all Sandostatin prices and generic prices |
View all Sandostatin LAR Depot prices and generic prices |
||||||||||||||||||||||||
| Dosage Form(s) Available | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
| Bynfezia Pen, Mycapssa, Sandostatin, Sandostatin LAR Depot | Other octreotide brands include: Bynfezia Pen, Mycapssa, Sandostatin LAR Depot | Other octreotide brands include: Bynfezia Pen, Mycapssa, Sandostatin | ||||||||||||||||||||||||
| Half Life The half-life of a drug is the time taken for the plasma concentration of a drug to reduce to half its original value. | ||||||||||||||||||||||||||
|
1.5 hours |
1.5 hours |
1.5 hours |
||||||||||||||||||||||||
| CSA Schedule ** View glossary of terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Category B
No proven risk in humans
See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 148 drugs are known to interact with octreotide:
|
A total of 148 drugs are known to interact with Sandostatin:
|
A total of 148 drugs are known to interact with Sandostatin LAR Depot:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
January 28, 2020 |
N/A |
N/A |
||||||||||||||||||||||||
| WADA Class View World Anti-Doping Agency classifications. | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient resources | ||||||||||||||||||||||||||
|
N/A |
||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
|
N/A |
||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
** The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.